Ken Griffin Ocular Therapeutix, Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$6.45 - $9.23 $200,595 - $287,053	-31,100 Reduced 23.74%	99,900 $869,000
Q2 2024 Aug 14, 2024	SELL	$4.2 - $8.69 $213,360 - $441,452	-50,800 Reduced 27.94%	131,000 $896,000
Q1 2024 May 15, 2024	BUY	$3.85 - $10.93 $507,045 - $1.44 Million	131,700 Added 262.87%	181,800 $1.65 Million
Q4 2023 Feb 14, 2024	BUY	$2.08 - $4.52 $45,968 - $99,891	22,100 Added 78.93%	50,100 $223,000
Q3 2023 Nov 14, 2023	SELL	$3.14 - $5.04 $446,508 - $716,688	-142,200 Reduced 83.55%	28,000 $87,000
Q2 2023 Aug 14, 2023	BUY	$4.6 - $7.64 $235,059 - $390,404	51,100 Added 42.91%	170,200 $878,000
Q1 2023 May 15, 2023	BUY	$2.79 - $6.27 $193,068 - $433,883	69,200 Added 138.68%	119,100 $627,000
Q4 2022 Feb 14, 2023	BUY	$2.61 - $4.41 $53,766 - $90,846	20,600 Added 70.31%	49,900 $140,000
Q3 2022 Nov 14, 2022	BUY	$4.09 - $6.5 $119,837 - $190,450	29,300 New	29,300 $122,000

171

138M

150K

225K

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $641M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.